Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Recruiting 10Active not recruiting 6Completed 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 35INDUSTRY 21NETWORK 6NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 6Disease 1

Interventions

Specimen Handling 18Cyclophosphamide 17Magnetic Resonance Spectroscopy 16Dexamethasone 15Cisplatin 14Vincristine 13Radiotherapy 13Radiation 11Etoposide 10Carboplatin 10durvalumab 9Radiotherapy, Intensity-Modulated 9Paclitaxel 9Doxorubicin 8Cytarabine 8Temozolomide 7Rituximab 7Prednisone 7Lenalidomide 7Irinotecan 7Gemcitabine 7Fluorouracil 7Docetaxel 7Bortezomib 7Biopsy 7daratumumab 6Platinum 6Leucovorin 6Capecitabine 6tremelimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × daratumumab × Clear all
NCT04166565 2026-04-20

EMN19

European Myeloma Network B.V.

Phase 2 Active not recruiting
41 enrolled
Plasma cell

Multiple Myeloma

NCT04667663 2026-04-13

CPD-DARA

Cancer Trials Ireland

Phase 1 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT05257083 2026-03-17

CARTITUDE-6

European Myeloma Network B.V.

Phase 3 Active not recruiting
759 enrolled
Plasma cell

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

European Myeloma Network B.V.

Phase 3 Active not recruiting
709 enrolled 17 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT04071457 2025-09-15

DRAMMATIC

SWOG Cancer Research Network

Phase 3 Active not recruiting
1,100 enrolled
Plasma cell

Multiple Myeloma

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡